Abstract: The present invention provides a simple and robust human liver cell-based system in which persistent hepatitis C infection, persistent hepatitis B infection or ethanol exposure induces a clinical Prognostic Liver Signature (PLS) high-risk gene signature. The cellular model system for hepatocellular carcinoma (HCC)/cirrhosis development and progression may be used in the screening of compounds useful in the treatment and/or prevention of cirrhosis and/or HCC as well as in the identification biomarkers for the prediction of liver disease (especially cirrhosis) progression and HCC. The present invention also relates to specific compounds that have been identified, using such screening methods, as useful in the treatment and/or the prevention of HCC/cirrhosis.
Type:
Application
Filed:
April 22, 2021
Publication date:
October 7, 2021
Applicants:
Universite de Strasbourg, Institut National de la Sante et de la Recherche Medicale, Institut Hospitalier Universitaire de Strasbourg, ICAHN School of Medicine at Mount Sinai
Abstract: Use of anti-Claudin 1 monoclonal antibodies and pharmaceutical compositions thereof, for the prevention and/or treatment of hepatocellular carcinoma in patients suffering from liver disease, in particular liver disease that is not associated with HCV infection or in patients who have been cured from HCV infection. Methods of preventing and/or treating hepatocellular carcinoma by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described. Experimental results with the hepatocarcinoma cell line HuH-7.5.1 are given.
Type:
Grant
Filed:
May 15, 2018
Date of Patent:
February 23, 2021
Assignees:
Universite de Strasbourg, Institut Hospitalier Universitaire de Strasbourg, Institut National de la Sante et de la Recherche Medicale
Inventors:
Thomas Baumert, Eric Robinet, Mirjam Zeisel
Abstract: Use of anti-Claudin 1 monoclonal antibodies and pharmaceutical compositions thereof, for the prevention and/or treatment of hepatocellular carcinoma in patients suffering from liver disease, in particular liver disease that is not associated with HCV infection or in patients who have been cured from HCV infection. Methods of preventing and/or treating hepatocellular carcinoma by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described. Experimental results with the hepatocarcinoma cell line HuH-7.5.1 are given.
Type:
Grant
Filed:
March 18, 2016
Date of Patent:
October 27, 2020
Assignees:
Institut Hospitalier Universitaire de Strasbourg, Institut National de la Sante et de la Recherche Medicale, Universite de Strasbourg
Inventors:
Thomas Baumert, Eric Robinet, Mirjam Zeisel
Abstract: A method for estimating a spatial distribution of the hazardousness of radiation doses for individuals evolving in a medical operating room defining a three-dimensional environment surrounding at least one source of radiation. First a three-dimensional model of the environment is obtained. Then a simulation of radiation doses attributable to ionizing radiation emitted from the source and scattered by the environment is computed in the model. Then, an image indicating the spatial distribution of the hazardousness for an individual of the radiation doses is generated and displayed. The three-dimensional model comprises models of individuals when the individuals are present in the environment and the image is a three-dimensional image generated for at least a portion of the model including said models of individuals.
Type:
Grant
Filed:
July 31, 2015
Date of Patent:
June 4, 2019
Assignees:
UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, INSTITUT HOSPITALIER UNIVERSITAIRE DE STRASBOURG